Clinical experience of using biosimilars in Crohn’s disease and their effectiveness-Reference-Cited by-同舟云学术

Clinical experience of using biosimilars in Crohn’s disease and their effectiveness

Author:

Sequier Léa¹²,Caron Bénédicte³⁴⁵⁶,Danese Silvio⁷⁸,Peyrin-Biroulet Laurent³⁴⁵⁶

Affiliation:

1. Department of Gastroenterology and Hepatology, Nîmes University Hospital, Carémeau Hospital, Nîmes, France

2. Department of Gastroenterology and Hepatology A, Saint-Éloi Hospital, Montpellier, France

3. Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France

4. INSERM, NGERE, University of Lorraine, Nancy, France

5. INFINY Institute, Nancy University Hospital, Vandœuvre-lès-Nancy, France

6. FHU-CURE, Nancy University Hospital, Vandœuvre-lès-Nancy, France

7. Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy

8. Department of Immunology, Transplantation and Infectious Disease, Università Vita-Salute San Raffaele, Milan, Italy

Publisher

Informa UK Limited

Link

Reference124 articles.

1. Remicade | European Medicines Agency [Internet]. [cited 2024 Feb 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remicade

2. Humira | European Medicines Agency [Internet]. [cited 2024 Feb 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/humira

4. Stelara | European Medicines Agency [Internet]. [cited 2024 Feb 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/stelara

5. Entyvio | European Medicines Agency [Internet]. [cited 2024 Feb 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio